Literature DB >> 27592117

Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.

Lilian Areal Marques1, Simone Cristine Semprebon2, Andressa Megumi Niwa2, Gláucia Fernanda Rocha D'Epiro2, Daniele Sartori2, Ângelo de Fátima3, Lúcia Regina Ribeiro4, Mário Sérgio Mantovani2.   

Abstract

Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cell lines. We investigated the antiproliferative effect of monastrol on human breast adenocarcinoma cells (MCF-7) and mammary epithelial cells (HB4a, non-tumoral). Monastrol treatment decreased cell viability only in MCF-7 tumor cells. Real-time cell growth kinetic analysis showed a decrease in the proliferation of MCF-7 cells exposed to monastrol, while in the HB4a cells, only a concentration of 100 μM was able to induce this effect. In a cell cycle analysis, exposure of MCF-7 cells to monastrol led to an increased population of cells in both the G1 and G2/M phases. In HB4a cells, the proportion of cells in the G2/M phase was increased. Monastrol led to an increased mitotic index in both cell lines. Monastrol was not able to induce cell death by apoptosis in any of the cell lines studied. Gene expression analysis was performed to measure the mRNA levels of cell cycle genes, DNA damage indicator gene, and apoptotic related genes. Treatment with monastrol induced in MCF-7 cells a 5-fold increase in the mRNA levels of the CDKN1A gene, an inhibitor of CDKs related with cell cycle arrest in response a stress stimulus, and a 2-fold decrease in CDKN1C mRNA levels in HB4a cells. These results provide evidence that monastrol has a greater antiproliferative effect on MCF-7 tumor cells compared with non-tumor HB4a cells; however, no selective is observed.

Entities:  

Keywords:  CDKN1A; HB4a; Kinesin 5; MCF-7; Monastrol

Mesh:

Substances:

Year:  2016        PMID: 27592117     DOI: 10.1007/s00210-016-1292-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  47 in total

1.  Cloning by differential screening of a Xenopus cDNA that encodes a kinesin-related protein.

Authors:  R Le Guellec; J Paris; A Couturier; C Roghi; M Philippe
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

2.  Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.

Authors:  Ulka Vijapurkar; Wei Wang; Ronald Herbst
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.

Authors:  Gregory M Chin; Ronald Herbst
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

Review 4.  The hallmarks of CDKN1C (p57, KIP2) in cancer.

Authors:  Edel Kavanagh; Bertrand Joseph
Journal:  Biochim Biophys Acta       Date:  2011-04-03

5.  Differentiation of trophoblast stem cells into giant cells is triggered by p57/Kip2 inhibition of CDK1 activity.

Authors:  Zakir Ullah; Matthew J Kohn; Rieko Yagi; Lyubomir T Vassilev; Melvin L DePamphilis
Journal:  Genes Dev       Date:  2008-11-01       Impact factor: 11.361

Review 6.  Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.

Authors:  Michael R Harrison; Kyle D Holen; Glenn Liu
Journal:  Clin Adv Hematol Oncol       Date:  2009-01

Review 7.  Cytoplasmic functions of the tumour suppressor p53.

Authors:  Douglas R Green; Guido Kroemer
Journal:  Nature       Date:  2009-04-30       Impact factor: 49.962

8.  Antitumor activity of a kinesin inhibitor.

Authors:  Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steve Weitman; Kenneth W Wood
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 10.  Mitotic functions of kinesin-5.

Authors:  Nick P Ferenz; Alyssa Gable; Pat Wadsworth
Journal:  Semin Cell Dev Biol       Date:  2010-01-28       Impact factor: 7.727

View more
  3 in total

Review 1.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

2.  Monastrol derivatives: in silico and in vitro cytotoxicity assessments.

Authors:  Zahra Bidram; Hajar Sirous; Ghadam Ali Khodarahmi; Farshid Hassanzadeh; Nasim Dana; Amir Ali Hariri; Mahboubeh Rostami
Journal:  Res Pharm Sci       Date:  2020-07-03

Review 3.  Role of motor proteins in human cancers.

Authors:  Iman Hassan Ibrahim; Amany Balah; Abrar Gomaa Abd Elfattah Hassan; Heba Gamal Abd El-Aziz
Journal:  Saudi J Biol Sci       Date:  2022-09-06       Impact factor: 4.052

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.